Pyxis Oncology’s (PYXS) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock. PYXS has been the topic of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a […]
HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock. PYXS has been the topic of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a […]
